Malignant (Necrotizing) Otitis Externa ent

Malignant (Necrotizing) Otitis Externa

Definition: An aggressive inflammatory condition of the external ear, spreading to the skull base.

Etiology & Risk Factors

  • Causative Organism: Pseudomonas aeruginosa (Most common).
  • Patient Profile:
    • Elderly.
    • Diabetics (Key risk factor).
    • Immunosuppressed patients.

Clinical Features

  • Pain: Excruciating otalgia (hallmark sign).
  • Otoscopy: Appearance of Granulations in the ear canal, typically at the Cartilaginous–Bony junction.
  • Nerve Involvement:
    • Facial Paralysis: Common.
    • Skull Base Spread: May involve jugular foramen causing multiple cranial nerve palsies (IX, X, XI).

Spread of Infection

  • Anteriorly: Temporomandibular fossa.
  • Posteriorly: Mastoid.
  • Medially: Middle ear and Petrous bone.

Diagnosis

⚠ Clinical Triad:
Elderly Diabetic + Severe Otalgia + Granulations at bony-cartilaginous junction.

Imaging Studies

Scan Type Features & Utility
CT Scan May show bony destruction (often not helpful early).
Gallium-67 Gold Standard for Monitoring.
• Taken up by monocytes/macrophages.
• Indicates soft tissue infection.
• Can be repeated every 3 weeks to assess response.
Technetium-99 Reveals bone infection (Osteomyelitis).
• Remains (+) for ~1 year.
Cannot be used to monitor disease resolution.

Treatment

1. General Measures

  • Strict control of Diabetes.
  • Aural Toilet: Removal of discharge, debris, granulations, and dead bone.

2. Antibiotic Therapy

Duration: Prolonged course (6–8 weeks or more).

Class Drugs & Details
Quinolones (Oral) Drug of Choice (Avoids admission).
Ciprofloxacin (750 mg OD).
• Ofloxacin / Levofloxacin.
• Can be combined with Rifampin.
IV Combo 1 Gentamicin + Ticarcillin.
*Caution: Gentamicin is ototoxic/nephrotoxic.
IV Combo 2 3rd Gen Cephalosporin (Ceftriaxone/Ceftazidime) + Aminoglycoside.

3. Surgery

Prolonged antibiotic treatment has largely replaced radical surgery/resections for this condition.

📚 Ref: Diseases of Ear, Nose & Throat (Dhingra)

💬 Comments

No comments:

Post a Comment